Format

Send to

Choose Destination
Methods Mol Biol. 2017;1499:223-236.

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.

Author information

1
TRON - Translational Oncology at the University Medical Center, Johannes Gutenberg University, Freiligrathstr. 12, Mainz, 55131, Germany.
2
Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, Mainz, 55131, Germany.
3
Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Mainz, 55131, Germany.
4
TRON - Translational Oncology at the University Medical Center, Johannes Gutenberg University, Freiligrathstr. 12, Mainz, 55131, Germany. sahin@uni-mainz.de.
5
Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, Mainz, 55131, Germany. sahin@uni-mainz.de.
6
Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Mainz, 55131, Germany. sahin@uni-mainz.de.

Abstract

Cancer accumulates 10s to 1000s of genomic mutations of which a fraction is immunogenic and may serve as an Achilles' heel of tumor cells. Mutation-specific T cells can recognize these antigens and destroy malignant cells. Strategies to immunotherapeutically address individual tumor mutations employing peptide or mRNA based vaccines are now actively investigated in mice and humans. An important step of determining the therapeutic potential of a mutanome vaccine is the detection of mutation reactive T-cell responses. In this chapter we provide protocols to identify and subtype mutation specific T cells in mice based on IFN-γ ELISpot and flow cytometry.

KEYWORDS:

Detection and subtyping of CD4+ and CD8+ T-cell responses; Neo-epitopes; mRNA

PMID:
27987153
DOI:
10.1007/978-1-4939-6481-9_14
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center